| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Quince Therapeutics Inc. | eDSP | Ataxia-Telangiectasia | Phase 3 | Data Released | oral | Genetic Disorder |
| Quince Therapeutics Inc. | EryDex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP)) - (NEAT) | Ataxia-Telangiectasia (A-T) | Phase 3 | Data Released | Intravenous | Genetic Disorder |
| Quince Therapeutics Inc. | Atuzaginstat - (GAIN) | Alzheimer’s disease | Phase 2/3 | Trial Discontinued | Oral | Neurology |
| Quince Therapeutics Inc. | Atuzaginstat | Oral potentially malignant disorders (OPMD) | Phase 2 | Looking for Funding | Oral | Oncology |
| Quince Therapeutics Inc. | Atuzaginstat | Parkinson's disease | Phase 2 | Trial Discontinued | Oral | Neurology |
| Quoin Pharmaceuticals Ltd. | QRX003 - (CL-QRX003-002) | Netherton Syndrome | Phase 3 | Ongoing | Topical | Genetic Disorder |
| Radiopharm Theranostics Limited | RAD 101 | Brain Mets | Phase 2b | Data Released | Oral | Oncology |
| Rafael Holdings Inc. Class B | Trappsol Cyclo - (TransportNPC) | Niemann-Pick Disease Type C | Phase 3 | Ongoing | Intravenous | Genetic Disorder |